Methyltrienolone is the most potent oral steroid ever obtained. This drug is a close relative of trenbolone and differs only in 17-alpha alkylation. This modification makes it significantly more powerful than the trenbolone. It is 120-300 times more potent than methyltestosterone. This is the most powerful steroid available on the market, a dose of 0.5-1mg is already sufficient for a powerful anabolic effect. Its activity is accompanied by strong toxicity, and this is what limits its use to laboratory conditions.
Methyltrienolone was first described in 1965. It is one of the most powerful anabolic steroids that has never been sold in pharmacies. This drug was used only in laboratory studies. Studies were conducted in the context of breast cancer treatment in the 1960s and 1970s. He slowed down, and in some cases reversed the process of tumor growth. Studies continued for a short time, because of the revealed toxicity. In the mid-1970s, methyltrinolone was tested in animals to determine binding to androgen receptors. He was very suitable for this purpose. His activity and resistance to binding blood proteins allowed him to easily become a reference substance. Because of its resistance to metabolism, metabolites of methyltrinolone did not interfere with the results of most experiments.
Methyltrienolone is not available as a prescription drug.
Methyltrienolone is a modified nandrolone. It differs: 1) by the addition of a methyl group at position 17a, which allows to protect the drug when taken orally, 2) by introducing a double bond between carbons 9 and 10, which reduces binding and slows the metabolism of the substance. As a result, we get a very strong steroid, with a long half-life and low ability to bind with blood proteins. Methyltrienolone differs from trenbolone only in the addition of a methyl group in the position of c17-alpha. This change changes the activity of the drug and it can not be called an oral analog of the trenbolone
Estrogenic side effects:
Methyltrienolone does not aromatize and does not have estrogenic activity. Dimethyltrilenolone has proximity to progesterone receptors. This can cause progesterone side effects, such as discontinuing testosterone production and increasing body fat. Progestins also increase the stimulating effect of estrogen in terms of breast tissue growth. There is such a strong interaction that gynecomastia can be caused by some progestins, without increasing the level of estrogen. The use of anti-estrogens can soften gynecomastia caused by progestagenic AAS.
Androgenic side effects:
Methyltrienolone is classified as anabolic, but androgenic side effects are very possible. It can be increased skin fatness, acne, hair growth on the body and face. Anabolic steroids can worsen male hair loss. Women in addition need to remember the potential virilizing effects of AAS. This may include coarsening of the voice, irregular periods, changes in the structure of the skin, growth of facial hair, and an increase in the clitoris. Methyltrienolone does not react with 5a-reductase and its androgenicity can not be altered by the parallel application of finasteride or dutasteride.